Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVR Anteris Technologies Global	$6.86 +0.4%	$6.73	$5.10 ▼ $8.79	$246.55M	N/A	133,415 shs	197,123 shs
LUCD Lucid Diagnostics	$1.39 +8.6%	$1.12	$0.63 ▼ $1.63	$82.49M	1.34	338,359 shs	1.22 million shs
SMTI Sanara MedTech	$32.39 +4.3%	$34.29	$26.00 ▼ $39.08	$283.12M	1.37	22,996 shs	16,873 shs
ZYXI Zynex	$2.97 +2.4%	$7.52	$2.77 ▼ $13.19	$94.58M	0.81	134,630 shs	670,090 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVR Anteris Technologies Global	-6.18%	-13.43%	-10.72%	+682,999,900.00%	+682,999,900.00%
LUCD Lucid Diagnostics	-3.03%	-7.91%	0.00%	+62.97%	+4.92%
SMTI Sanara MedTech	-2.66%	-3.51%	-10.03%	-10.39%	-16.76%
ZYXI Zynex	-14.96%	-60.11%	-61.23%	-64.37%	-77.15%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	2.2542 of 5 stars	3.6	2.0	0.0	0.0	1.9	1.7	0.6
SMTI Sanara MedTech	2.5848 of 5 stars	3.5	2.0	0.0	0.0	3.3	1.7	0.6
ZYXI Zynex	3.328 of 5 stars	3.2	1.0	0.0	0.0	2.2	2.5	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVR Anteris Technologies Global	3.00	Buy	$16.50	140.52% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.63	160.79% Upside
SMTI Sanara MedTech	3.00	Buy	$47.00	45.11% Upside
ZYXI Zynex	2.33	Hold	$10.25	245.12% Upside

Current Analyst Ratings Breakdown

Latest LUCD, SMTI, AVR, and ZYXI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/12/2025	ZYXI Zynex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $15.00
3/12/2025	ZYXI Zynex	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$11.00 ➝ $5.50
3/12/2025	ZYXI Zynex	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
1/23/2025	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
1/22/2025	SMTI Sanara MedTech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$44.00 ➝ $44.00
1/8/2025	AVR Anteris Technologies Global	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
1/7/2025	AVR Anteris Technologies Global	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
1/7/2025	AVR Anteris Technologies Global	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$9.00
1/7/2025	AVR Anteris Technologies Global	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$22.00
12/23/2024	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00

(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVR Anteris Technologies Global	$2.71M	90.94	N/A	N/A	N/A	∞
LUCD Lucid Diagnostics	$4.19M	19.69	N/A	N/A	($0.47) per share	-2.96
SMTI Sanara MedTech	$78.06M	3.63	N/A	N/A	$5.22 per share	6.20
ZYXI Zynex	$193.67M	0.49	$0.16 per share	18.01	$1.36 per share	2.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVR Anteris Technologies Global	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	-$52.67M	-$1.14	N/A	N/A	N/A	-1,069.87%	N/A	-123.54%	3/24/2025 (Estimated)
SMTI Sanara MedTech	-$4.30M	-$0.99	N/A	N/A	N/A	-10.71%	-19.86%	-10.91%	3/24/2025 (Estimated)
ZYXI Zynex	$9.73M	$0.15	19.80	6.32	N/A	2.49%	13.05%	3.78%	4/28/2025 (Estimated)

Latest LUCD, SMTI, AVR, and ZYXI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/24/2025	N/A	LUCD Lucid Diagnostics	-$0.15	N/A	N/A	N/A	$1.42 million	N/A
3/24/2025	N/A	SMTI Sanara MedTech	-$0.28	N/A	N/A	N/A	$22.75 million	N/A
3/11/2025	Q4 2024	ZYXI Zynex	$0.09	-$0.02	-$0.11	-$0.02	$53.65 million	$45.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVR Anteris Technologies Global	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	1.18	1.14
SMTI Sanara MedTech	0.76	2.23	2.02
ZYXI Zynex	1.66	3.94	3.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVR Anteris Technologies Global	N/A
LUCD Lucid Diagnostics	74.01%
SMTI Sanara MedTech	8.10%
ZYXI Zynex	29.68%

Insider Ownership

Company	Insider Ownership
AVR Anteris Technologies Global	N/A
LUCD Lucid Diagnostics	8.80%
SMTI Sanara MedTech	54.10%
ZYXI Zynex	52.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVR Anteris Technologies Global	138	35.94 million	N/A	N/A
LUCD Lucid Diagnostics	70	59.34 million	54.12 million	No Data
SMTI Sanara MedTech	60	8.74 million	4.01 million	Not Optionable
ZYXI Zynex	1,100	31.85 million	15.25 million	Optionable

LUCD, SMTI, AVR, and ZYXI Headlines

Recent News About These Companies

Zynex, Inc. Just Missed EPS By 55%: Here's What Analysts Think Will Happen Next

March 14 at 11:07 AM | finance.yahoo.com

Zynex (NASDAQ:ZYXI) Stock Rating Lowered by LADENBURG THALM/SH SH

March 14 at 2:55 AM | americanbankingnews.com

Zynex price target lowered to $15 from $17 at H.C. Wainwright

March 13 at 7:57 PM | markets.businessinsider.com

Zynex, Inc. (ZYXI) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

March 13 at 7:57 PM | tmcnet.com

Securities Fraud Investigation Into Zynex, Inc. (ZYXI) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

March 13 at 3:00 PM | businesswire.com

Zynex, Inc. (ZYXI) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

March 13 at 2:00 PM | businesswire.com

HC Wainwright Lowers Zynex (NASDAQ:ZYXI) Price Target to $15.00

March 13 at 8:11 AM | marketbeat.com

Zynex (NASDAQ:ZYXI) Downgraded by Royal Bank of Canada to "Sector Perform"

March 13 at 7:44 AM | marketbeat.com

Zynex (NASDAQ:ZYXI) Cut to "Neutral" at LADENBURG THALM/SH SH

March 13 at 7:44 AM | marketbeat.com

Ladenburg Thalmann Downgrades Zynex (ZYXI)

March 13 at 4:51 AM | msn.com

Zynex (NASDAQ:ZYXI) Releases Q1 2025 Earnings Guidance

March 12 at 8:36 PM | marketbeat.com

Securities Fraud Investigation Into Zynex, Inc. (ZYXI) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

March 12 at 7:00 PM | businesswire.com

Zynex Shares Fall After Tricare Suspends Payments

March 12 at 6:46 PM | marketwatch.com

Zynex, Inc.: Zynex Reports Fourth Quarter and Full Year 2024 Financial Results

March 12 at 6:46 PM | finanznachrichten.de

Zynex downgraded to Sector Perform from Outperform at RBC Capital

March 12 at 6:46 PM | markets.businessinsider.com

Zynex, Inc. (NASDAQ:ZYXI) Q4 2024 Earnings Call Transcript

March 12 at 6:46 PM | msn.com

Zynex (NASDAQ:ZYXI) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPS

March 12 at 4:51 PM | marketbeat.com

INVESTOR ALERT: Investigation of Zynex, Inc. (ZYXI) Announced by Holzer & Holzer, LLC

March 12 at 1:29 PM | globenewswire.com

Zynex's Sell-Off Creates A Speculative Buying Opportunity

March 12 at 12:01 PM | seekingalpha.com

Zynex to Cut 15% of Workforce After Tricare Suspends Payments

March 12 at 12:26 AM | marketwatch.com

Stocks to Watch: Zynex, Finance of America, Groupon

March 12 at 12:26 AM | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, SMTI, AVR, and ZYXI Company Descriptions

Anteris Technologies Global NASDAQ:AVR

$6.86 +0.03 (+0.44%)

As of 04:00 PM Eastern

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

Lucid Diagnostics NASDAQ:LUCD

$1.39 +0.11 (+8.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 +0.03 (+1.80%)

As of 06:35 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Sanara MedTech NASDAQ:SMTI

$32.39 +1.34 (+4.32%)

Closing price 04:00 PM Eastern

Extended Trading

$32.30 -0.09 (-0.26%)

As of 04:01 PM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Zynex NASDAQ:ZYXI

$2.97 +0.07 (+2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.99 +0.02 (+0.67%)

As of 06:27 PM Eastern

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time